Back
ZyVersa Therapeutics 10K Form
Sell
8
ZVSA
ZyVersa Therapeutics
Last Price:
1.12
Seasonality Move:
-78.1%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive ZVSA News And Ratings
See the #1 stock for the next 7 days that we like better than ZVSA
ZVSA Financial Statistics
Sales & Book Value
Annual Sales: | -- |
---|---|
Cash Flow: | $-644.4K |
Price / Cash Flow: | 0 |
Annual Sales: | $6.54 |
Price / Book: | 0.38 |
Profitability
EPS (TTM): | -113.74790 |
---|---|
Net Income (TTM): | $-21.33M |
Gross Margin: | -- |
Return on Equity: | 0% |
Return on Assets: | 0% |
ZyVersa Therapeutics Earnings Forecast
Key ZyVersa Therapeutics Financial Ratios
- The Interest Expense is -3.04% of Operating Income.
- Per Share Earnings over the last 4 years have been positive in 1 years.
ZyVersa Therapeutics Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | ZVSA |
Website: | zyversa.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 0 |
Quick Ratio: | 0 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
ZVSA Technical Analysis vs Fundamental Analysis
Sell
8
ZyVersa Therapeutics (ZVSA)
is a Sell
Is ZyVersa Therapeutics a Buy or a Sell?
-
ZyVersa Therapeutics stock is rated a Sell
The current ZyVersa Therapeutics [ZVSA] share price is $1.13. The Score for ZVSA is 8, which is 84% below its historic median score of 50, and infers higher risk than normal.